Close

Ovid Therapeutics' (OVID) TAK-935/OV935 Receives Orphan Drug Designation from FDA for Treatment of Dravet Syndrome

December 5, 2017 8:04 AM EST Send to a Friend
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login